AKKARAJU SRINIVAS 4

What Happened
Akkaraju Srinivas, reported as a 10% owner of Mineralys Therapeutics (MLYS), was granted equity awards on February 19, 2026: 6,200 restricted stock units (RSUs) recorded as an acquisition and 8,300 RSUs recorded as a derivative acquisition — 14,500 units in total. Both grants were issued for no cash consideration (price $0.00), so the reported value at grant is $0. These are awards/compensation, not open-market purchases or sales.

Key Details

• Transaction date(s) and price(s): Feb 19, 2026; 6,200 RSUs @ $0.00 (acquired) and 8,300 RSUs @ $0.00 (derivative).
• Total units granted: 14,500 RSUs; reported grant value $0 at issuance.
• Vesting (F1): These RSUs are contingent rights to receive one share per RSU and vest in one annual installment following the grant date.
• Derivative explanation: The 8,300 units are reported as derivative awards (contingent on vesting).
• Beneficial ownership note (F2): The filing discloses related holdings — 588,235 shares held by Samsara Opportunity Fund, L.P. and 5,282,783 shares held by Samsara BioCapital L.P.; Dr. Akkaraju has voting and investment power over those fund-held shares and disclaims beneficial ownership except to the extent of any pecuniary interest.
• Other footnote (F3): The filing also references a separate stock option vesting schedule (12 monthly installments), which appears unrelated to these RSU grants.
• Filing timeliness: Reported period 2026-02-19 and filed 2026-02-20 (filed next day — timely).

Context
RSU grants are compensation that convert to shares only upon vesting and can be forfeited if vesting conditions aren’t met; they do not represent an immediate open-market purchase or sale. As a reported 10% owner operating through investment vehicles, these awards reflect equity allocation and compensation arrangements rather than a direct personal open-market investment signal.